| Dr Eric Peter Wilkinson, MD | |
|
1209 N Summerbrook Ave Ste 100, Meridian, ID 83642-8750 | |
| (208) 938-5823 | |
| (208) 938-5306 |
| Full Name | Dr Eric Peter Wilkinson |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 23 Years |
| Location | 1209 N Summerbrook Ave Ste 100, Meridian, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114906013 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | M-15220 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Regional Medical Center | Boise, ID | Hospital |
| Saint Alphonsus Regional Medical Center | Boise, ID | Hospital |
| St Lukes Magic Valley Medical Center | Twin falls, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Idaho Ear Clinic Llc | 2668703687 | 5 |
News Archive
An estimated 7 million people will shop for individual health coverage this fall in the new online health insurance marketplaces, with another 2 million seeking coverage through the law's small business program. Federal and state officials are working full tilt to have them ready in time.
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.
Research undertaken by RCSI University of Medicine and Health Sciences suggests that integrating pharmacists into general practice (GP) teams facilitates collaboration to optimize treatment plans for patients with long-term medical needs and alleviate pressures on GP practices.
New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.
› Verified 6 days ago
| Entity Name | Idaho Ear Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154976983 PECOS PAC ID: 2668703687 Enrollment ID: O20191004002956 |
News Archive
An estimated 7 million people will shop for individual health coverage this fall in the new online health insurance marketplaces, with another 2 million seeking coverage through the law's small business program. Federal and state officials are working full tilt to have them ready in time.
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.
Research undertaken by RCSI University of Medicine and Health Sciences suggests that integrating pharmacists into general practice (GP) teams facilitates collaboration to optimize treatment plans for patients with long-term medical needs and alleviate pressures on GP practices.
New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric Peter Wilkinson, MD 1209 N. Summerbrook Ave. Ste 100, Meridian, ID 83642 Ph: (208) 938-5823 | Dr Eric Peter Wilkinson, MD 1209 N Summerbrook Ave Ste 100, Meridian, ID 83642-8750 Ph: (208) 938-5823 |
News Archive
An estimated 7 million people will shop for individual health coverage this fall in the new online health insurance marketplaces, with another 2 million seeking coverage through the law's small business program. Federal and state officials are working full tilt to have them ready in time.
NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its second Phase II clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formulation under development for continuous subcutaneous administration through a patch pump. It is designed to provide steady levodopa blood levels for the treatment of Parkinson's disease.
Research undertaken by RCSI University of Medicine and Health Sciences suggests that integrating pharmacists into general practice (GP) teams facilitates collaboration to optimize treatment plans for patients with long-term medical needs and alleviate pressures on GP practices.
New data presented today further demonstrate the efficacy of Instanyl in management of breakthrough cancer pain. The data which were presented at the 6th congress of the European Federation of Chapters of the International Association for the Study of Pain (EFIC) are from a multinational, crossover trial comparing Instanyl with oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in patients with cancer.
› Verified 6 days ago
Dr. James Vincent Crawford, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1209 N Summerbrook Ave Ste 100, Meridian, ID 83642 Phone: 208-938-5823 Fax: 208-938-5306 | |
Lance Wayne Coleman, MD Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 520 S Eagle Rd, #1223, Meridian, ID 83642 Phone: 208-888-4368 | |
Dr. Jacob Scott Majors, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 875 S Vanguard Way Ste 200, Meridian, ID 83642 Phone: 208-809-2895 Fax: 208-809-2896 | |
Dr. Peter James Killian, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1157 N Summerbrook Ave Ste 120, Meridian, ID 83642 Phone: 208-593-4484 Fax: 208-593-4491 | |
John Boyajian, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 3085 E Magic View Dr # 140, Meridian, ID 83642 Phone: 208-433-9300 Fax: 208-433-9854 |